Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
20 9월 2023 - 5:01AM
Replimune Group, Inc. (NASDAQ: REPL), a clinical stage
biotechnology company pioneering the development of a novel
portfolio of oncolytic immunotherapies, today announced the grant
of inducement equity awards to Emily Hill, the Company’s newly
appointed Chief Financial Officer.
The inducement awards consist of a non-qualified stock option to
purchase 125,000 shares of the Company's common stock and
restricted stock units representing 83,330 shares of the Company's
common stock. The option has an exercise price of $18.00 per share,
which is equal to the closing price of the Company's common stock
on the date of grant. The option has a 10-year term and will vest
over four years, with 25% of the underlying shares vesting on the
one-year anniversary of the grant date and the remainder vesting
monthly for three years thereafter. The restricted stock units vest
in approximately four equal annual installments beginning on August
15, 2024.
The inducement awards were approved by the compensation
committee of the Company's board of directors in reliance on the
employment inducement exception under Nasdaq Listing Rule
5635(c)(4). While the inducement awards were granted outside of the
Company’s 2018 Equity Incentive Plan, the awards will have terms
and conditions consistent with those set forth under the plan.
About Replimune Replimune Group, Inc.,
headquartered in Woburn, MA, was founded in 2015 with the mission
to transform cancer treatment by pioneering the development of
novel oncolytic immunotherapies. Replimune’s proprietary RPx
platform is based on a potent HSV-1 backbone with added payloads
intended to maximize immunogenic cell death and the induction of a
systemic anti-tumor immune response. The RPx platform is intended
to provide a unique dual local and systemic mechanism of action
consisting of direct selective virus-mediated killing of the tumor
resulting in the release of tumor derived antigens and altering of
the tumor microenvironment to ignite a strong and durable systemic
response. This MOA is expected to be synergistic with most
established and experimental cancer treatment modalities, and, with
an attractive safety profile the RPx platform has the versatility
to be developed alone or combined with a variety of other treatment
options. For more information, please visit www.replimune.com.
Investor Inquiries Chris BrinzeyWestwicke, an
ICR Company339.970.2843chris.brinzey@westwicke.com
Media InquiriesArleen
GoldenbergReplimune917.548.1582media@replimune.com
Replimune (NASDAQ:REPL)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Replimune (NASDAQ:REPL)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024